Drugs / Vapendavir
Vapendavir
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05962645 | May → Dec 2023 | chronic obstructive pulmonary disease | Altesa Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02877264 | Jun → Aug 2016 | — | Aviragen Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02204501 | May → Jun 2014 | — | Biota Scientific Management Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02101866 | Mar → May 2014 | — | Biota Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06834295 | Mar 2025 | — | Altesa Biosciences, Inc. | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT07610395 | May 2026 → Nov 2027 expected | viral respiratory tract infection | Altesa Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06149494 | Nov 2023 → Mar 2025 | chronic obstructive pulmonary disease, common cold, enterovirus infectious disease | Altesa Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01175226 | Aug 2010 → Mar 2012 | common cold | Biota Scientific Management Pty Ltd | Completed | Met primary |
| Phase 2 | NCT03024177 | ? → Apr 2017 | viral respiratory tract infection | Vaxart | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02367313 Comparator | Feb 2015 → Dec 2016 | asthma | Biota Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-05-26 | Altesa Biosciences, Inc. | Regulatory Altesa Biosciences To Initiate Clinical Trials Of Promising Antiviral altesabio.com ↗
Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and global viral threats, has U.S. Food & Drug Administration approval to proceed with a clinical study of a promising antiviral treatment, vapendavir. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-26 | Altesa Biosciences, Inc. | Altesa Biosciences To Initiate Clinical Trials Of Promising Antiviral altesabio.com ↗ |
| 2021-07-07 | Vaxart | Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset vaxart.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vapendavir | “Vapendavir 1000 mg” NCT07610395 ↗ |
| Known as | BTA798 | “A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Vapendavir (BTA798) on the Pharmacokinetics of Orally Administered Midazolam, a CYP3A4 Substrate, in Healthy...” NCT02204501 ↗ |
| Known as | VPV | “Vapendavir (VPV) is potent virostatic antiviral agent active against all known enterovirus species.” NCT05962645 ↗1“Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection” NCT06149494 ↗ |
| Action | Inhibit | “VPV binds to the viral capsid, thereby inhibiting viral attachment to the target cell and, independently, preventing release of viral RNA” NCT05962645 ↗ |
| Modality | Small molecule | — CHEMBL2062774 ↗ |
| Route | Oral | “oral bioavailability of a single dose” NCT02101866 ↗ |